Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

By Fineline Cube #Cancer #Clinical trial approval / initiation #Huahai Pharmaceutical #SHA: 600521

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical trial evaluating HB0025 in combination with chemotherapy for the first-line treatment of advanced or recurrent endometrial cancer. The in-house developed anti-PD-L1/VEGF bispecific fusion protein represents Huahai’s entry into the dual-target immuno-oncology space, leveraging synergistic “immune enhancement + anti-angiogenesis” mechanisms.

Clinical Trial Overview

ParameterDetail
Study PhasePhase III (pivotal)
Treatment RegimenHB0025 + chemotherapy combination
IndicationAdvanced or recurrent endometrial cancer (first-line)
Line of TherapyFirst-line (treatment-naïve or early recurrent)
DeveloperZhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521)
Announcement Date19 Mar 2026

Product Profile & Mechanism

AttributeHB0025 Specification
FormatAnti-PD-L1/VEGF bispecific fusion protein
Target 1PD-L1 – blocks tumor immune evasion pathway
Target 2VEGF – inhibits tumor angiogenesis
Binding AffinityHigh-affinity binding to both targets simultaneously
MechanismDual antitumor action: immune enhancement + anti-angiogenesis
Therapeutic StrategySynergistic modulation of tumor immune microenvironment and vascular normalization

Strategic Context & Competitive Landscape

FactorImplication
Endometrial Cancer Incidence~80,000 new cases annually in China; rising with obesity/diabetes trends; 15–20% advanced/metastatic at diagnosis
First-Line StandardCarboplatin/paclitaxel + pembrolizumab (PD-1) for MMR-deficient; limited options for MMR-proficient patients
PD-1/VEGF RationaleValidated by lenvatinib/pembrolizumab in endometrial cancer (KEYNOTE-775); HB0025 offers single-molecule convenience vs. combination
Bispecific AdvantageCoordinated pharmacokinetics; reduced dosing complexity; potential for improved safety profile vs. small molecule TKIs + ICI combinations
Competitive LandscapeAkesobio (PD-1/VEGF, Phase II), Sino Biopharm (PD-L1/VEGF, preclinical); Huahai aims for first-to-market bispecific in China

Development Strategy & Market Impact

InitiativeStrategic Value
First-Line PositioningCaptures largest addressable population before resistance develops
Chemotherapy CombinationStandard backbone enables pragmatic trial design and regulatory familiarity
MMR-Agnostic PotentialDual mechanism may benefit both MMR-deficient (PD-1 responsive) and MMR-proficient (angiogenesis-dependent) subtypes
Global RightsHuahai retains worldwide rights; potential for ex-China partnership post-China Phase III data
  • Clinical Timeline: Phase III enrollment Q2 2026; interim analysis 2028; NDA filing 2029 assuming positive PFS/OS benefit
  • Revenue Forecast: Peak sales RMB 800 million–1.2 billion annually in China assuming 15–20% first-line advanced endometrial cancer market share; global potential $300+ million

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase III execution, clinical efficacy outcomes, and commercial potential for HB0025 in endometrial cancer. Actual results may differ due to competitive dynamics with PD-1/VEGF combinations, chemotherapy backbone selection, and reimbursement negotiations in the gynecologic oncology market.-Fineline Info & Tech

600521_20260319_PDDKDownload

Related Post

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Fineline Cube
Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Fineline Cube
Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

Fineline Cube

You Missed

Company Drug

Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients

Company Drug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

Company Drug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

Company Drug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis